# Frequently Asked Questions – Statement of Investigator (Form FDA 1572):  Guidance for Sponsors, Clinical Investigators, and IRBs - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/information-sheet/frequently-asked-questions-statement-of-investigator-form-fda-1572-guidance-for-sponsors-clinical-investigators-and-irbs/d997c3d8-2f5b-4be6-bdf5-3fcb57d6fe85

> FDA guidance document: Frequently Asked Questions – Statement of Investigator (Form FDA 1572):  Guidance for Sponsors, Clinical Investigators, and IRBs. Issue date: June 04, 2010. Get complete insights and analysis.

---

## Details

- Title: Frequently Asked Questions – Statement of Investigator (Form FDA 1572):  Guidance for Sponsors, Clinical Investigators, and IRBs
- Communication Type: Information Sheet
- Product Type: biologics
- Office Name: Office of the Commissioner
- Office URL: /offices/office-of-the-commissioner/79483979-9582-427f-ac3d-46c715811424
- Issue Date: 2010-06-04
- Last Changed: 2020-04-21
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2008-D-0406">FDA-2008-D-0406</a>

## Related Documents

- [IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed:  Guidance for IRBs, Clinical Investigators, and Sponsors](https://www.globalkeysolutions.net/guidances/guidance-document/irb-responsibilities-for-reviewing-the-qualifications-of-investigators-adequacy-of-research-sites-and-the-determination-of-whether-an-indide-is-needed-guidance-for-irbs-clinical-investigators-and-sponsors/797294db-f9b3-4c0d-b100-f6ee4b81ebae)
- [IRB Continuing Review After Clinical Investigation Approval:  Guidance for IRBs, Clinical Investigators, and Sponsors](https://www.globalkeysolutions.net/guidances/guidance-document/irb-continuing-review-after-clinical-investigation-approval-guidance-for-irbs-clinical-investigators-and-sponsors/7c18de8c-1544-4b72-a67a-3a861d29c31c)
- [Codevelopment of Two or More New Investigational Drugs for Use in Combination](https://www.globalkeysolutions.net/guidances/guidance-document/codevelopment-of-two-or-more-new-investigational-drugs-for-use-in-combination/6a704e0b-f05e-4e65-91b9-7d60ac493505)